Abstract |
A combined oral contraceptive (COC) containing the progestogen drospirenone (pronounced dro-spi-re-known) plus the oestrogen ethinylestradiol ([symbol: see text] Yasmin--Schering Health Care) is now available in the UK. Company advertising claims that Yasmin is "truly different", as reliable and safe as other COCs and is "the pill for well-being", with "no associated weight gain" and "a demonstrable positive effect" on premenstrual symptoms and skin condition. Such claims have also appeared in the lay media. Are they justified?
|
Authors | |
Journal | Drug and therapeutics bulletin
(Drug Ther Bull)
Vol. 40
Issue 8
Pg. 57-9
(Aug 2002)
ISSN: 0012-6543 [Print] England |
PMID | 12216337
(Publication Type: Journal Article, Review)
|
Chemical References |
- Androstenes
- Contraceptives, Oral, Combined
- Mineralocorticoid Receptor Antagonists
- Progesterone Congeners
- drospirenone
|
Topics |
- Adolescent
- Adult
- Androstenes
- Body Weight
(drug effects)
- Contraceptives, Oral, Combined
- Female
- Humans
- Mineralocorticoid Receptor Antagonists
- Progesterone Congeners
- Randomized Controlled Trials as Topic
|